McMullen officially becomes new Agilent CEO
This article was originally published in Clinica
Executive Summary
Mike McMullen has become the new CEO of Agilent Technologies, replacing Bill Sullivan, who will be a company advisor until he retires at the end of October. New leader Mr McMullen was previously president and chief operating officer of the company, and has spent over 30 years with Agilent and Hewlett-Packard (which the former spun off from in 1999). Bio-analytical measurement specialist Agilent has been through a transitional period, announcing in September 2013 that it was splitting into two companies: one focused on life sciences and diagnostics, and the other on its electronic measurement (EM) business. It spun off the EM franchise, Keysight Technologies, in November 2014, after announcing in September that Mr Sullivan would retire from the new-look Agilent, and Mr McMullen take up the reins.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.